Trinity Biotech (TRIB) Total Liabilities (2009 - 2025)

Trinity Biotech (TRIB) has reported Total Liabilities for 17 consecutive years, with $177.1 million the latest figure, recorded in Q4 2025.

• Quarterly Total Liabilities rose 27.93% year-over-year to $177.1 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $177.1 million (up 27.93% YoY) and the FY2025 annual result came in at $177.1 million, up 27.93% from the prior year.
• Total Liabilities grew to $177.1 million in Q4 2025 per TRIB's latest filing, from $149.2 million in the prior quarter.
• Over the last five years, Total Liabilities for TRIB reached as high as $177.1 million in Q4 2025 and fell as low as $81.1 million in Q3 2023.
• A 5-year average of $114.6 million and a median of $116.2 million in 2021 frame the typical range for Total Liabilities.
• Annual changes were most pronounced in 2022 — Total Liabilities retreated 27.07% — and 2024, when it soared 66.06%.
• Year by year, Total Liabilities stood at $119.2 million in 2021, then slipped by 20.92% to $94.3 million in 2022, then declined by 11.56% to $83.4 million in 2023, then surged by 66.06% to $138.5 million in 2024, then grew by 27.93% to $177.1 million in 2025.
• According to Business Quant data, Total Liabilities over the past three periods registered $177.1 million, $149.2 million, and $138.5 million for Q4 2025, Q2 2025, and Q4 2024 respectively.